Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
21 Feb 2022
21 Feb 2022
Historique:
pubmed:
13
1
2022
medline:
13
1
2022
entrez:
12
1
2022
Statut:
epublish
Résumé
Third COVID-19 vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults. We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and Omicron (BA.1) strains from pre-vaccine up to one month following the third dose, in 151 adults aged 24-98 years who received COVID-19 mRNA vaccines. Following two vaccine doses, humoral immunity was weaker, less functional and less durable in older adults, where a higher number of chronic health conditions was a key correlate of weaker responses and poorer durability. Third doses boosted antibody binding and function to higher levels than second-doses, and induced responses in older adults that were comparable in magnitude to those in younger adults. Humoral responses against Omicron were universally weaker than against the ancestral strain after both second and third doses; nevertheless, after three doses, anti-Omicron responses in older adults reached equivalence to those in younger adults. After three vaccine doses, the number of chronic health conditions, but not age per se, was the strongest consistent correlate of weaker humoral responses. Results underscore the immune benefits of third COVID-19 vaccine doses, particularly in older adults.
Sections du résumé
BACKGROUND
BACKGROUND
Third COVID-19 vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults.
METHODS
METHODS
We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and Omicron (BA.1) strains from pre-vaccine up to one month following the third dose, in 151 adults aged 24-98 years who received COVID-19 mRNA vaccines.
RESULTS
RESULTS
Following two vaccine doses, humoral immunity was weaker, less functional and less durable in older adults, where a higher number of chronic health conditions was a key correlate of weaker responses and poorer durability. Third doses boosted antibody binding and function to higher levels than second-doses, and induced responses in older adults that were comparable in magnitude to those in younger adults. Humoral responses against Omicron were universally weaker than against the ancestral strain after both second and third doses; nevertheless, after three doses, anti-Omicron responses in older adults reached equivalence to those in younger adults. After three vaccine doses, the number of chronic health conditions, but not age per se, was the strongest consistent correlate of weaker humoral responses.
CONCLUSION
CONCLUSIONS
Results underscore the immune benefits of third COVID-19 vaccine doses, particularly in older adults.
Identifiants
pubmed: 35018381
doi: 10.1101/2022.01.06.22268745
pmc: PMC8750654
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Commentaires et corrections
Type : UpdateIn
Références
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166
pubmed: 34437519
Nat Commun. 2021 Dec 10;12(1):7217
pubmed: 34893611
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
J Infect Dis. 2022 Mar 2;225(5):785-792
pubmed: 34850049
Lancet. 2020 May 30;395(10238):1715-1725
pubmed: 32405103
Emerg Infect Dis. 2022 Mar;28(3):756-759
pubmed: 35107418
Science. 2022 Feb 11;375(6581):678-680
pubmed: 35040667
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
N Engl J Med. 2021 Oct 21;385(17):1627-1629
pubmed: 34525276
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Nature. 2022 Jan;601(7891):110-117
pubmed: 34758478
J Infect Dis. 2022 Apr 1;225(7):1129-1140
pubmed: 34888688
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Nat Commun. 2021 Nov 4;12(1):6379
pubmed: 34737312
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
JAMA Netw Open. 2020 Jul 1;3(7):e2015957
pubmed: 32697325
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
Cell. 2021 Nov 11;184(23):5699-5714.e11
pubmed: 34735795
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
Nat Immunol. 2022 Jan;23(1):50-61
pubmed: 34853448
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Immun Ageing. 2021 Aug 20;18(1):34
pubmed: 34416887
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Microbiol Spectr. 2022 Oct 26;10(5):e0204622
pubmed: 36190405
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Sci Transl Med. 2022 Feb 09;14(631):eabj6824
pubmed: 34931886
Emerg Microbes Infect. 2022 Dec;11(1):337-343
pubmed: 34935594
mBio. 2022 Apr 26;13(2):e0361721
pubmed: 35229637
Science. 2021 Mar 25;:
pubmed: 33766944
BMC Geriatr. 2020 Oct 16;20(1):409
pubmed: 33066750
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Cell Host Microbe. 2021 Jul 14;29(7):1076-1092
pubmed: 34237248
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246